R&D Tax Refund
0
Patrys has today confirmed a $1,188,581 Research and Development (R&D) Tax Incentive Refund for the 2020/2021 financial year. We greatly…
PAT-DX1 Engineering Update
Patrys has today announced the completion of the first engineering run for its lead asset PAT-DX1. The purification of PAT-DX1…
Beacon | Interview with Dr James Campbell
Patrys CEO and MD, Dr James Campbell, has been interviewed by the drug development experts Beacon Intelligence about the Company’s…
$7.8m Capital Raise
Patrys has today announced a $7.8 million capital raising via a Placement and fully underwritten Rights Issue. These funds will…
Change of Company Secretary
Patrys is today welcoming the appointment of a new Company Secretary to our Senior Management Team, Stefan Ross, who was…
Video Presentation | AusBiotech Investor Presentation
Patrys’ CEO and MD, Dr James Campbell joined other biotech executives at the Australia Biotech Invest & Partnering Conference this…
Important Notice – Fraudulent Emails
Patrys Ltd has been informed that fraudulent emails purporting to be sent from our Company are in circulation. The fraudulent…
Quarterly Activities Report and 4C Quarterly Cash Flow Report
Patrys (ASX:PAB) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the quarter ended 30…
AusBiotech Conference | Australia Biotech Invest & Partnering Conference
Patrys CEO, Dr James Campbell, has composed some thoughts about his participation in AusBiotech’s upcoming events – the annual AusBiotech…
Patrys PATDX3 antibody drug conjugate significantly increases survival in animal model
Patrys today released the latest data from its completed proof-of-concept study demonstrating the potential of its full-sized deoxymab antibody, PAT-DX3,…